---
title: "NOT.DE (NOT.DE) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NOT.DE/news.md"
symbol: "NOT.DE"
name: "NOT.DE"
parent: "https://longbridge.com/en/quote/NOT.DE.md"
datetime: "2026-05-20T18:47:08.445Z"
locales:
  - [en](https://longbridge.com/en/quote/NOT.DE/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NOT.DE/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NOT.DE/news.md)
---

# NOT.DE (NOT.DE) — Related News

### [Porton: The Slovenia R&D and production base project is facing significant controversy, which is expected to have a major adverse impact on the financial condition and operating performance for the fiscal year 2026](https://longbridge.com/en/news/286222927.md)
*2026-05-13T08:26:08.000Z*
> Porton announced that its wholly-owned subsidiary PSI is facing compliance issues with its research and production base 

### [Thrive Capital, Alphabet To Lead Isomorphic Labs $2 Billion Fundraising Goal](https://longbridge.com/en/news/285983463.md)
*2026-05-11T18:40:17.000Z*
> Thrive Capital and Alphabet are leading a $2 billion fundraising effort for Isomorphic Labs, an AI-driven drug discovery

### [Kepler Capital  Remains a Buy on Novartis AG (NOVN)](https://longbridge.com/en/news/285825757.md)
*2026-05-10T01:58:39.000Z*
> Kepler Capital analyst David Evans has maintained a Buy rating on Novartis AG (NOVN) as of May 8, with a price target of

### [Construction begins on Novartis’ RLT centre in Texas, US](https://longbridge.com/en/news/285719524.md)
*2026-05-08T09:54:49.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [Key facts: Novartis wins EU OK for Rhapsido; builds Morrisville API site](https://longbridge.com/en/news/284858814.md)
*2026-05-01T02:04:51.000Z*
> Novartis has received EU approval for Rhapsido (remibrutinib) for adults with chronic spontaneous urticaria resistant to

### [Assessing Novartis (SWX:NOVN) Valuation After Recent Share Weakness And Long Term Gains](https://longbridge.com/en/news/284816715.md)
*2026-04-30T17:55:44.000Z*
> Novartis (SWX:NOVN) has experienced recent share price fluctuations, with a 1-day return of 1.2% and a year-to-date retu

### [Weekly Buzz: FDA Okays Saphnelo Pen, EC Clears Acromegaly Drug, SNGX Slumps, LGND Snaps Up XOMA](https://longbridge.com/en/news/284786732.md)
*2026-04-30T13:54:03.000Z*
> This week's biotech news highlights significant regulatory approvals and acquisitions. Crinetics received EU approval fo

### [Deutsche Bank  Sticks to Their Buy Rating for Novartis AG (NOVN)](https://longbridge.com/en/news/284552232.md)
*2026-04-29T10:40:55.000Z*
> Deutsche Bank analyst Emmanuel Papadakis has reaffirmed a Buy rating for Novartis AG (NOVN) with a price target of CHF13